Wu Jieping Medical Foundation   Report issue

Foundation Phase 2 Phase 3
Founded: Beijing China (2002)

Organization Overview

First Clinical Trial
2009
NCT01017679
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Wu Jieping Medical Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Brain Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Recurrence (Phase 2)

Sepsis (Phase 3)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 12